AstraZeneca at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
AstraZeneca takes part in 5 sessions at Antibody Engineering 2026 in San Diego. Its program centers on antibody-drug conjugates, including how translational medicine drives their clinical success, and on T cell engagers. Highlights include a CD30 conjugate that carries two different drug payloads using non-natural amino acids, and a CD8-guided T cell engager with a wide safety margin in preclinical studies.
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases. | Talk Sun Dec 13 11:00am–11:45am Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Chair Wed Dec 16 2:10pm–2:15pm Talk Wed Dec 16 2:15pm–2:45pm |
Find decision makers at AstraZeneca
Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction